Effects of Topical Low Dose Preservative-free Hydrocortisone on Intraocular Pressure
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04536129 |
|
Recruitment Status :
Completed
First Posted : September 2, 2020
Last Update Posted : October 1, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Ocular Surface Disease Glaucoma | Drug: Hydrocortisone (CORTIVIS ®) | Not Applicable |
The ocular surface comprises the cornea, conjunctiva, eyelids and lacrimal glands and any disorder in these structures can be classified as an ocular surface disorder (OSD). OSD includes Dry Eye Disease (DED), blepharitis and meibomian gland dysfunction (MDG), allergic eye diseases (AED), chemical and thermal burns; all these conditions can severely affect eyesight and quality of life, and sometime even blindness. Patients with OSD can develop photophobia, corneal scarring, intermittent blurred vision, pain, limited ability to perform daily activities, reduced vitality, poor general health and, in many cases, depression.
Glaucoma, one of the leading causes of irreversible blindness, is an optic neuropathy characterized by thinning of retinal nerve fiber layer and increase of optic disc cupping , whose main risk factor is closely related to the intraocular pressure (IOP) levels. Thus, the management of the disease consists in the lowering IOP through medical, laser or surgical therapy . However, IOP reduction is most commonly achieved using topical ocular medications, which often contain preservatives employed to maintain stability and sterility of the product. Preservatives can be associated with undesirable adverse effects such as allergy, local irritation and inflammation . The long-term use of anti-glaucoma medications produces several alterations of ocular surface components, especially at the conjunctival level where epithelial modifications, dendritic cell activation, conjunctiva-associated lymphoid tissue activation, and goblet cell (GCs) loss easily occur GCs play crucial tasks in the homeostasis of the ocular surface being the main source of mucoproteins, essential to maintain tear film stability. Thus, the loss of GCs progressively leads to the happening of an iatrogenic OSD . Moreover, advancing age is a significant risk factor for both OSD and glaucoma, further complicated by treatments for each condition, which can interact among them and yield counterproductive effects . For these reason glaucoma is often associated with OSD .Ocular surface inflammation is crucial in the pathophysiology of OSD, therefore anti-inflammatory therapy, including corticosteroids, may be of benefit to OSD patients . However, in susceptible individuals steroid-induced glaucoma or ocular hypertension can occur after steroid use. Individuals who develop an increase in IOP following steroid use are referred to as "steroid responders" . In a recent study Kallab et al. have found that dry eye treatment with low hydrocortisone dose reduced ocular inflammation without inducing increases in IOP ; glaucomatous patients were excluded from this study. Herein we evaluate the safety and efficacy of hydrocortisone eye drops in the treatment of OSD patients with and without glaucoma.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 90 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Effects of Topical Low Dose Preservative-free Hydrocortisone on Intraocular Pressure in Patients With and Without Glaucoma |
| Actual Study Start Date : | November 4, 2019 |
| Actual Primary Completion Date : | March 4, 2020 |
| Actual Study Completion Date : | March 4, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Group A: glaucoma
OSD patients with glaucoma
|
Drug: Hydrocortisone (CORTIVIS ®)
Once enrolled all the patients had to instill topical low dose (1,005 mg) preservative-free hydrocortisone (CORTIVIS ®- Medivis, Catania, Italy) 2 times daily in each eye for two weeks. |
|
Active Comparator: Group B: no glaucoma
OSD patients without glaucoma
|
Drug: Hydrocortisone (CORTIVIS ®)
Once enrolled all the patients had to instill topical low dose (1,005 mg) preservative-free hydrocortisone (CORTIVIS ®- Medivis, Catania, Italy) 2 times daily in each eye for two weeks. |
- Intraocular pressure(IOP) [ Time Frame: 2 weeks ]IOP evaluation at time zero (T0), after 1 (T1) and two weeks of therapy (T2).
- OSDI (Ocular Surface Disease Index) questionnaire [ Time Frame: 2 weeks ]OSDI record at time zero (T0), after 1 (T1) and two weeks of therapy (T2).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- age of at least 18 years
- diagnosis of OSD (Ocular Surface Disease)
- normal ophthalmic findings except history of OSD for at least 3 months, and current therapy with topical lubricants for at least 3 months
- POAG (primary open-angle glaucoma ) patients on medical therapy
Exclusion Criteria:
- clinically significant slit lamp findings at screening visit except OSD
- participation in a clinical trial in the 4 weeks preceding the screening visit
- symptoms of a clinically relevant illness in the 3 weeks before the screening visit
- presence/ history of a severe medical or surgical condition
- intake of parasympathomimetic or antipsychotic drugs
- wearing of contact lenses
- previous refractive laser surgery (e.g photorefractive keratectomy-PRK, laser assisted in situ keratomileusis-LASIK, etc.)
- history of IOP increase caused by systemic or topical treatment with corticosteroids
- IOP greater than 22 mmHg
- treatment with corticosteroids in the 4 weeks preceding the study
- types of glaucoma other than POAG
- ocular infection or clinically significant inflammation
- ocular surgery in the 3 months preceding the study
- Sjögren's syndrome, Stevens-Johnson syndrome
- history of allergic conjunctivitis
- pregnancy, planned pregnancy or lactating
- known hypersensitivity to any component of study medication
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04536129
| Italy | |
| University of Molise | |
| Campobasso, Italy | |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Ciro Costagliola, Full Professor in Ophthalmology, University of Molise |
| ClinicalTrials.gov Identifier: | NCT04536129 |
| Other Study ID Numbers: |
CTS 11/2019 |
| First Posted: | September 2, 2020 Key Record Dates |
| Last Update Posted: | October 1, 2021 |
| Last Verified: | September 2021 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Glaucoma Ocular Hypertension Eye Diseases Hydrocortisone Anti-Inflammatory Agents |